Given that Δ133p53 tumors have increased TAMs, PDL-1, and T cells, investigation of inhibition or stimulation of TLR4 is warranted as a potential therapeutic strategy for cancer and potentially extended to other conditions [5, 6, 10]. This evidence concerns the gene TLR4 and cancer.